• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

靶向β淀粉样蛋白：阿尔茨海默病免疫治疗方法的临床综述

Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.

作者信息

Lobello Kasia, Ryan J Michael, Liu Enchi, Rippon Gregory, Black Ronald

机构信息

Department of Clinical Sciences, Pfizer Inc., Collegeville, PA 19426, USA.

出版信息

Int J Alzheimers Dis. 2012;2012:628070. doi: 10.1155/2012/628070. Epub 2012 Jan 15.

DOI:10.1155/2012/628070
PMID:22292124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3265072/
Abstract

As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the development of various immunotherapeutic approaches targeting beta amyloid. This paper reviews active and passive approaches aimed at beta amyloid, with a focus on clinical trial data.

摘要

随着阿尔茨海默病（AD）的社会和经济负担持续加重，对减缓疾病进展疗法的需求也日益增加。β淀粉样蛋白长期以来一直被认为是AD的病理标志，在过去十年中，针对β淀粉样蛋白的各种免疫治疗方法取得了显著进展。本文综述了针对β淀粉样蛋白的主动和被动方法，并重点关注临床试验数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daa4/3265072/f5c6d9feda72/IJAD2012-628070.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daa4/3265072/360f15d5cb4b/IJAD2012-628070.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daa4/3265072/f5c6d9feda72/IJAD2012-628070.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daa4/3265072/360f15d5cb4b/IJAD2012-628070.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daa4/3265072/f5c6d9feda72/IJAD2012-628070.002.jpg

相似文献

1
Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.靶向β淀粉样蛋白：阿尔茨海默病免疫治疗方法的临床综述
Int J Alzheimers Dis. 2012;2012:628070. doi: 10.1155/2012/628070. Epub 2012 Jan 15.
2
The past, present, and future of disease-modifying therapies for Alzheimer's disease.阿尔茨海默病的疾病修饰治疗的过去、现在和未来。
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(10):757-771. doi: 10.2183/pjab.93.048.
3
Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.基于tau蛋白的阿尔茨海默病治疗方法——一篇综述短文
Gerontology. 2014;60(5):381-5. doi: 10.1159/000358875. Epub 2014 Apr 8.
4
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease.ACU193：一种有望验证阿尔茨海默病淀粉样β寡聚体假说的免疫疗法。
Front Neurosci. 2022 Apr 26;16:848215. doi: 10.3389/fnins.2022.848215. eCollection 2022.
5
Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives.阿尔茨海默病的免疫疗法：现状与未来展望。
J Prev Alzheimers Dis. 2021;8(4):534-551. doi: 10.14283/jpad.2021.52.
6
Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.探索针对减轻阿尔茨海默病中与淀粉样蛋白-β级联相关事件的治疗剂的潜力。
Int J Mol Sci. 2020 Oct 9;21(20):7443. doi: 10.3390/ijms21207443.
7
Recent advancements toward therapeutic vaccines against Alzheimer's disease.针对阿尔茨海默病的治疗性疫苗的最新进展。
Expert Rev Vaccines. 2018 Aug;17(8):707-721. doi: 10.1080/14760584.2018.1500905. Epub 2018 Aug 9.
8
The Alzheimer's disease drug development landscape.阿尔茨海默病药物研发全景图。
Alzheimers Res Ther. 2021 Nov 11;13(1):186. doi: 10.1186/s13195-021-00927-z.
9
Immunotherapeutic approaches for Alzheimer's disease.阿尔茨海默病的免疫治疗方法。
Neuron. 2015 Mar 18;85(6):1162-76. doi: 10.1016/j.neuron.2014.12.064.
10
Alzheimer's Disease: A Brief History of Immunotherapies Targeting Amyloid β.阿尔茨海默病：靶向淀粉样蛋白β的免疫疗法简史。
Int J Mol Sci. 2023 Feb 15;24(4):3895. doi: 10.3390/ijms24043895.

引用本文的文献

1
Herpes simplex virus-1 infection alters microtubule-associated protein Tau splicing and promotes Tau pathology in neural models of Alzheimer's disease.单纯疱疹病毒1型感染会改变微管相关蛋白Tau的剪接，并在阿尔茨海默病的神经模型中促进Tau病理变化。
Brain Pathol. 2025 Mar 26:e70006. doi: 10.1111/bpa.70006.
2
intronic expansion identified by poly-glycine-arginine pathology increases Alzheimer's disease risk.由聚甘氨酸 - 精氨酸病理学鉴定出的内含子扩增增加了阿尔茨海默病风险。
Proc Natl Acad Sci U S A. 2025 Feb 18;122(7):e2416885122. doi: 10.1073/pnas.2416885122. Epub 2025 Feb 12.
3
Natural products against tau hyperphosphorylation-induced aggregates: Potential therapies for Alzheimer's disease.

本文引用的文献

1
The worldwide economic impact of dementia 2010.2010 年全球痴呆症的经济影响。
Alzheimers Dement. 2013 Jan;9(1):1-11.e3. doi: 10.1016/j.jalz.2012.11.006.
2
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.淀粉样蛋白相关成像异常在淀粉样蛋白修饰治疗试验中的研究：来自阿尔茨海默病协会研究圆桌工作组的建议。
Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351.
3
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.
针对tau蛋白过度磷酸化诱导的聚集体的天然产物：阿尔茨海默病的潜在疗法。
Arch Pharm (Weinheim). 2025 Jan;358(1):e2400721. doi: 10.1002/ardp.202400721.
4
A Molecular Integrative Study on the Inhibitory Effects of WRR and ERW on Amyloid β Peptide (1-42) Polymerization and Cell Toxicity.WRR和ERW对淀粉样β肽（1-42）聚合及细胞毒性抑制作用的分子整合研究
Polymers (Basel). 2023 Nov 8;15(22):4356. doi: 10.3390/polym15224356.
5
Amyloid-β in Alzheimer's disease - front and centre after all?阿尔茨海默病中的β淀粉样蛋白——终究是处于核心地位吗？
Neuronal Signal. 2023 Jan 6;7(1):NS20220086. doi: 10.1042/NS20220086. eCollection 2023 Mar.
6
A Neuroprotective Action of Quercetin and Apigenin through Inhibiting Aggregation of Aβ and Activation of TRKB Signaling in a Cellular Experiment.在细胞实验中，槲皮素和芹菜素通过抑制β-淀粉样蛋白（Aβ）聚集和激活TRKB信号发挥神经保护作用。
Biomol Ther (Seoul). 2023 May 1;31(3):285-297. doi: 10.4062/biomolther.2022.136. Epub 2023 Jan 17.
7
Bioactive Compounds and Their Derivatives: An Insight into Prospective Phytotherapeutic Approach against Alzheimer's Disease.生物活性化合物及其衍生物：对阿尔茨海默病潜在植物治疗方法的深入了解。
Oxid Med Cell Longev. 2022 Apr 11;2022:5100904. doi: 10.1155/2022/5100904. eCollection 2022.
8
A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro.一种具有治疗潜力的新型 D-氨基酸肽（ISAD1）可抑制神经毒性疾病相关突变 Tau 的聚集，并在体外预防 Tau 毒性。
Alzheimers Res Ther. 2022 Jan 21;14(1):15. doi: 10.1186/s13195-022-00959-z.
9
RRY Inhibits Amyloid-β Peptide Aggregation and Neurotoxicity.RRY抑制β-淀粉样肽聚集和神经毒性。
J Alzheimers Dis Rep. 2021 Jun 8;5(1):479-495. doi: 10.3233/ADR-210012. eCollection 2021.
10
Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.通过 CpG 寡脱氧核苷酸刺激先天免疫可改善老年松鼠猴的阿尔茨海默病病理。
Brain. 2021 Aug 17;144(7):2146-2165. doi: 10.1093/brain/awab129.
从阿尔茨海默病皮层中分离得到的可溶性淀粉样β蛋白二聚体直接诱导 Tau 过度磷酸化和神经突变性。
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5819-24. doi: 10.1073/pnas.1017033108. Epub 2011 Mar 18.
4
Decreased clearance of CNS beta-amyloid in Alzheimer's disease.阿尔茨海默病患者中枢神经系统β-淀粉样蛋白清除减少。
Science. 2010 Dec 24;330(6012):1774. doi: 10.1126/science.1197623. Epub 2010 Dec 9.
5
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.人血丙种球蛋白通过多种机制在阿尔茨海默病的小鼠模型中提供针对 Aβ 毒性的保护。
J Neuroinflammation. 2010 Dec 7;7:90. doi: 10.1186/1742-2094-7-90.
6
Apolipoprotein E ε4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis.载脂蛋白 E ε4 在全球不同人群阿尔茨海默病患者中的流行率存在差异：一项系统文献回顾和荟萃分析。
Dement Geriatr Cogn Disord. 2011;31(1):20-30. doi: 10.1159/000321984. Epub 2010 Dec 1.
7
A single ascending dose study of bapineuzumab in patients with Alzheimer disease.一项评估阿尔茨海默病患者中 bapineuzumab 单剂量递增的研究。
Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198-203. doi: 10.1097/WAD.0b013e3181c53b00.
8
Murine models of Alzheimer's disease and their use in developing immunotherapies.阿尔茨海默病的小鼠模型及其在开发免疫疗法中的应用。
Biochim Biophys Acta. 2010 Oct;1802(10):847-59. doi: 10.1016/j.bbadis.2010.05.004. Epub 2010 May 13.
9
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.阿尔茨海默病患者单次注射淀粉样β单克隆抗体后血浆和脑脊液中淀粉样β的安全性及变化
Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73. doi: 10.1097/WNF.0b013e3181cb577a.
10
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.人抗淀粉样蛋白-β主动免疫对神经突形态和 Tau 病理学的有益作用。
Brain. 2010 May;133(Pt 5):1312-27. doi: 10.1093/brain/awq056. Epub 2010 Mar 31.